Several regulatory and clinical events mark ongoing industry progress. The FDA approved Leo Pharma’s topical cream, Anzupgo, for chronic hand eczema—the first approved treatment for this indication in the U.S. Cryofocus received FDA breakthrough device designation for its cryoablation system for asthma, prompting a stock surge. Companies report positive clinical data updates, such as AstraZeneca’s gefurulimab in myasthenia gravis passing phase III endpoints. Meanwhile, multiple companies have raised financing or reshuffled leadership, signaling continued dynamism amid healthcare innovation.